Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Jun
14
2023
New York Landlords May Get Stuck with the Bill for Unlicensed Cannabis Sticker Shops Sheppard, Mullin, Richter & Hampton LLP
Mar
11
2020
FDA Commissioner Signals Enforcement Policy, Advancement of Research for CBD Products Sheppard, Mullin, Richter & Hampton LLP
Jun
21
2023
The Drug Price Negotiation Program Faces Pushback from Private and Public Industry Participants Sheppard, Mullin, Richter & Hampton LLP
May
11
2020
The Expansion of Cardiovascular Procedures in the ASC Setting Sheppard, Mullin, Richter & Hampton LLP
Jul
13
2020
FDA Announces Plans to Resume Domestic On-site Inspections Sheppard, Mullin, Richter & Hampton LLP
Feb
5
2024
Cannabis Rescheduling: HHS Findings and Legal Implications Sheppard, Mullin, Richter & Hampton LLP
Apr
1
2024
FDCA Preemption: A Powerful Tool for Defending Class Actions Sheppard, Mullin, Richter & Hampton LLP
Jan
13
2011
New Defense Authorization Act Imposes Buy American Act Mandate for Photovoltaics Sheppard, Mullin, Richter & Hampton LLP
Aug
9
2021
California Breaks New Ground With OCal: Answers to Key Questions About “Comparable-to-Organic” Cannabis Sheppard, Mullin, Richter & Hampton LLP
Nov
2
2018
OIG Report on Topical Compounded Drug Prescribing, Marketing and Billing Practices Signals Heightened Administrative and Enforcement Scrutiny Sheppard, Mullin, Richter & Hampton LLP
Feb
16
2022
Restructure This! Episode 3: Canada: Cannabis Boom or Bust? [PODCAST] Sheppard, Mullin, Richter & Hampton LLP
Mar
1
2022
Treasury Department Recommends Antitrust Reform in Alcohol Markets Sheppard, Mullin, Richter & Hampton LLP
Mar
18
2022
OIG Advisory Opinion Alert: Yet Another Favorable Decision for Medical Device Manufacturers Sheppard, Mullin, Richter & Hampton LLP
Apr
29
2022
International Cooperation under China’s Proposed Implementing Rules for Human Genetic Resources Management Sheppard, Mullin, Richter & Hampton LLP
May
8
2019
AAFCO Issues Updated Guidelines Regarding Hemp in Animal Food Sheppard, Mullin, Richter & Hampton LLP
May
20
2019
Location Matters – Manufacturing Insights from FDA’s Annual Report on Drug Quality Sheppard, Mullin, Richter & Hampton LLP
Jun
20
2022
Supreme Court Saves Hospitals from $1.6B Cut to 340B Program Sheppard, Mullin, Richter & Hampton LLP
Dec
16
2014
Sandoz and Celltrion Decline the Invitation to Dance: Biosimilars Challenge the Applicability of the BPCIA’s Exchange Provisions Before Bringing Suit Sheppard, Mullin, Richter & Hampton LLP
Jun
23
2022
FDA Issues Untitled Letter to Althera Pharmaceuticals for Statements Relating to ROSZET® Sheppard, Mullin, Richter & Hampton LLP
Feb
19
2015
Go For De Novo: FDA’s Revised Approach to Medical Device Accessories Sheppard, Mullin, Richter & Hampton LLP
Sep
30
2019
CBD Industry Beware: The False Labeling Class Action Has Arrived Sheppard, Mullin, Richter & Hampton LLP
Oct
3
2019
Third Circuit Holds that SLUSA Does Not Preclude Class Action Opt-Outs from Pursuing Individual Actions Sheppard, Mullin, Richter & Hampton LLP
Dec
27
2022
FDA Expands Inspection Guidance to Apply to Device Manufacturers Sheppard, Mullin, Richter & Hampton LLP
Oct
30
2019
BREAKING NEWS: USDA Releases Interim Final Hemp Rule Sheppard, Mullin, Richter & Hampton LLP
Mar
7
2023
DEA Proposes Rule for Post-PHE Telemedicine Sheppard, Mullin, Richter & Hampton LLP
Apr
26
2023
Withdrawal of Drug Approval Highlights Risk of Accelerated Approval Pathway Sheppard, Mullin, Richter & Hampton LLP
Jun
4
2023
FDA Cracking Down on Unapproved HCT/Ps with Fourth Untitled Letter of 2023 Sheppard, Mullin, Richter & Hampton LLP
Jun
11
2023
Is this “Good-Bye” to the Two-Year Mandatory Minimum in Healthcare Fraud Cases? Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins